Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples